Trulieve debuts on NYSE

Florida-based MSO Trulieve went public on the New York Stock Exchange in an important first for the licensed cannabis industry. The move follows the Trump administrations rescheduling of MED to a schedule III substance under the Controlled Substances Act and comes weeks before DEA hearings are set to begin on rescheduling REC.

Trulieve CEO Kim Rivers has gained a reputation as the industry's "Trump whisperer." His unexpected decision to reschedule MED but delay action on REC

Log in or become a WeedWeek Member to read this article.